WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H408190
CAS#: 863971-24-8
Description: Mc-MMAE is a monomethyl auristatin E (MMAE) derative having a reactive linker (maleimidocaproyl). MMAE is a potent tubulin inhibitor with antitumor activity. The maleimido group in Mc-MMAE is reactive nucleophilic functional groups such as thiol. Mc-MMAE is useful to make drug-antibody conjugate (ADC).
Hodoodo Cat#: H408190
Name: Mc-MMAE
CAS#: 863971-24-8
Chemical Formula: C49H78N6O10
Exact Mass: 910.58
Molecular Weight: 911.195
Elemental Analysis: C, 64.59; H, 8.63; N, 9.22; O, 17.56
Synonym: Mc-MMAE; Maleimidocaproyl-monomethylauristatin E;
IUPAC/Chemical Name: 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-N-methylhexanamide
InChi Key: UGJOTJHSQWBROP-AXJCKIDNSA-N
InChi Code: InChI=1S/C49H78N6O10/c1-13-32(6)44(37(64-11)29-41(59)54-28-20-23-36(54)46(65-12)33(7)47(61)50-34(8)45(60)35-21-16-14-17-22-35)53(10)49(63)42(30(2)3)51-48(62)43(31(4)5)52(9)38(56)24-18-15-19-27-55-39(57)25-26-40(55)58/h14,16-17,21-22,25-26,30-34,36-37,42-46,60H,13,15,18-20,23-24,27-29H2,1-12H3,(H,50,61)(H,51,62)/t32-,33+,34+,36-,37+,42-,43-,44-,45+,46+/m0/s1
SMILES Code: O=C1N(CCCCCC(N(C)[C@H](C(N[C@@H](C(C)C)C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C3=CC=CC=C3)O)C)=O)C)CCC2)=O)OC)C)=O)=O)C(C)C)=O)C(C=C1)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 911.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Chon H, Kanamori S, Hibino K, Nagahara T, Suzuki T, Ohara K, Narumi H. ez- ADiCon: A novel glyco-remodeling based strategy that enables preparation of homogenous antibody-drug conjugates via one-step enzymatic transglycosylation with payload-preloaded bi-antennary glycan complexes. Bioorg Med Chem Lett. 2022 Dec 27;80:129117. doi: 10.1016/j.bmcl.2022.129117. Epub ahead of print. PMID: 36584791.
2: Wu G, Li L, Liu M, Chen C, Wang G, Jiang Z, Qin Y, He L, Li H, Cao J, Gu H. Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model. Cancer Cell Int. 2022 Dec 27;22(1):417. doi: 10.1186/s12935-022-02839-w. PMID: 36572921; PMCID: PMC9793597.
3: Hoffman-Censits J, Maldonado L. Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context. Onco Targets Ther. 2022 Dec 15;15:1519-1529. doi: 10.2147/OTT.S370900. PMID: 36545447; PMCID: PMC9762760.
4: Paulus J, Nachtigall B, Meyer P, Sewald N. RGD Peptidomimetic MMAE-Conjugate Addressing Integrin αVβ3-Expressing Cells with High Targeting Index*. Chemistry. 2022 Dec 1. doi: 10.1002/chem.202203476. Epub ahead of print. PMID: 36454662.
5: Jaramillo ML, Sulea T, Durocher Y, Acchione M, Schur MJ, Robotham A, Kelly JF, Goneau MF, Robert A, Cepero-Donates Y, Gilbert M. A glyco-engineering approach for site-specific conjugation to Fab glycans. MAbs. 2023 Jan- Dec;15(1):2149057. doi: 10.1080/19420862.2022.2149057. PMID: 36447399.
6: Evans RJ, Perkins DW, Selfe J, Kelsey A, Birch GP, Shipley JM, Schipper K, Isacke CM. Endo180 (MRC2) antibody-drug conjugate for the treatment of sarcoma. Mol Cancer Ther. 2022 Nov 18:MCT-22-0312. doi: 10.1158/1535-7163.MCT-22-0312. Epub ahead of print. PMID: 36399638.
7: Cho H, Shim MK, Moon Y, Song S, Kim J, Choi J, Kim J, Lee Y, Park JY, Kim Y, Ahn CH, Kim MR, Yoon HY, Kim K. Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy. Pharmaceutics. 2022 Oct 7;14(10):2131. doi: 10.3390/pharmaceutics14102131. PMID: 36297566; PMCID: PMC9609178.
8: Khan T, Lyons NJ, Gough M, Kwah KKX, Cuda TJ, Snell CE, Tse BW, Sokolowski KA, Pearce LA, Adams TE, Rose SE, Puttick S, Pajic M, Adams MN, He Y, Hooper JD, Kryza T. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics. 2022 Oct 3;12(16):6915-6930. doi: 10.7150/thno.78171. PMID: 36276654; PMCID: PMC9576610.
9: Su Z, Xie F, Xu X, Liu L, Xiao D, Zhou X, Li S. Development of a nitroreductase-dependent theranostic payload for antibody-drug conjugate. Bioorg Chem. 2022 Dec;129:106190. doi: 10.1016/j.bioorg.2022.106190. Epub 2022 Oct 6. PMID: 36242983.
10: Zhang Y, Wang Y, Uslu S, Venkatachalapathy S, Rashidian M, Schaefer JV, Plückthun A, Distefano MD. Enzymatic Construction of DARPin-Based Targeted Delivery Systems Using Protein Farnesyltransferase and a Capture and Release Strategy. Int J Mol Sci. 2022 Sep 29;23(19):11537. doi: 10.3390/ijms231911537. PMID: 36232839; PMCID: PMC9569580.
11: Zana A, Galbiati A, Gilardoni E, Bocci M, Millul J, Sturm T, Stucchi R, Elsayed A, Nadal L, Cirillo M, Roll W, Stegger L, Asmus I, Backhaus P, Schäfers M, Neri D, Cazzamalli S. Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors. Clin Cancer Res. 2022 Dec 15;28(24):5440-5454. doi: 10.1158/1078-0432.CCR-22-1788. PMID: 36215129.
12: Glover ZK, Wecksler A, Aryal B, Mehta S, Pegues M, Chan W, Lehtimaki M, Luo A, Sreedhara A, Rao VA. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species. MAbs. 2022 Jan-Dec;14(1):2122957. doi: 10.1080/19420862.2022.2122957. PMID: 36151884; PMCID: PMC9519010.
13: Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, Van Rietschoten K, Watcham SM, Scott HS, Brown AN, Park PU, Campbell C, Haines E, Lahdenranta J, Skynner MJ, Jeffrey P, Keen N, Lee K. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Mol Cancer Ther. 2022 Dec 2;21(12):1747-1756. doi: 10.1158/1535-7163.MCT-21-0875. PMID: 36112771.
14: Pei M, Liu T, Ouyang L, Sun J, Deng X, Sun X, Wu W, Huang P, Chen YL, Tan X, Liu X, Zhu P, Liu Y, Wang D, Wu J, Wang Q, Wang G, Gong L, Qin Q, Wang C. Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera. J Pharm Anal. 2022 Aug;12(4):645-652. doi: 10.1016/j.jpha.2021.11.005. Epub 2021 Nov 24. PMID: 36105165; PMCID: PMC9463470.
15: Suthe SR, Yao HP, Weng TH, Wang MH. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-Drug Conjugates for Eradication of Triple-Negative Breast Cancer Stem Cells. Curr Cancer Drug Targets. 2022 Aug 25. doi: 10.2174/1568009622666220825115528. Epub ahead of print. PMID: 36028965.
16: Olatunji FP, Pun M, Herman JW, Romero O, Maniatopoulos M, Latoche JD, Parise RA, Guo J, Beumer JH, Anderson CJ, Berkman CE. Modular Smart Molecules for PSMA- Targeted Chemotherapy. Mol Cancer Ther. 2022 Nov 3;21(11):1701-1709. doi: 10.1158/1535-7163.MCT-22-0160. PMID: 35999662; PMCID: PMC9842478.
17: Heitz N, Greer SC, Halford Z. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer. Ann Pharmacother. 2022 Aug 12:10600280221118370. doi: 10.1177/10600280221118370. Epub ahead of print. PMID: 35962528.
18: Miyazaki T, Chen S, Florinas S, Igarashi K, Matsumoto Y, Yamasoba T, Xu ZQ, Wu H, Gao C, Kataoka K, Christie RJ, Cabral H. A Hoechst Reporter Enables Visualization of Drug Engagement In Vitro and In Vivo: Toward Safe and Effective Nanodrug Delivery. ACS Nano. 2022 Aug 23;16(8):12290-12304. doi: 10.1021/acsnano.2c03170. Epub 2022 Aug 9. PMID: 35942986.
19: Chen X, Liu F, Yu X, Li L, Yan J, Chen X, Liu Q, Liu B. An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer. Eur J Med Chem. 2022 Nov 5;241:114617. doi: 10.1016/j.ejmech.2022.114617. Epub 2022 Jul 19. PMID: 35932567.
20: Gibiansky L, Passey C, Voellinger J, Gunawan R, Hanley WD, Gupta M, Winter H. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1358-1370. doi: 10.1002/psp4.12850. Epub 2022 Aug 6. PMID: 35932175; PMCID: PMC9574719.
